A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).
• Women with a history of invasive breast cancer or DCIS
• Currently taking aromatase inhibitors or tamoxifen
• Not receiving hormone replacement therapy for minimum of one month
• Age 18 years or older
• Self-reported hot flashes at least fourteen times per week
• Self-reported hot flashes for at least one month
• If receiving non-tricyclic antidepressants (venlafaxine, paroxetine, citalopram, sertraline, etc.) or gabapentin, no change in regimen in past 4 weeks.